Voydeya Receives FDA Approval as Supplemental Treatment with Ravulizumab or Eculizumab for Managing Extravascular Hemolysis in Adult Patients with PNH Voydeya (danicopan) has received approval in the United States for use alongside ravulizumab or eculizumab in treating extravascular hemolysis (EVH) in adults dia...
Find MoreFDA Approves RINVOQ as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease AbbVie announced that the FDA had approved RINVOQ® (upadacitinib) for treating people with moderately to highly active Crohn's disease who have had an unsatisfactory response or intolerance to one or more TNF blockers. Thi...
Find MoreBiogen terminates USD 217 Million ALS Pact with Karyopharm Biogen has backed out of the four-year-old partnership with Karyopharm on a drug candidate for the neurological disease amyotrophic lateral sclerosis, which could have cost the US biotech up to USD 217 million. The 2018 agreement that granted Biogen righ...
Find MoreThe autoimmune diseases are frequently incapacitating and, in some circumstances, fatal. There are currently more than 80 identified autoimmune disorders, such as Rheumatoid Arthritis, Crohn's Disease, Plaque Psoriasis, Ulcerative Colitis, Myasthenia Gravis, and many more with symptoms ranging from mild to severe. ...
Find MoreInnoCare Receives Go-ahead for Clinical Trial of TYK2 Inhibitor ICP-332 in China InnoCare, a biopharma firm developing novel therapies for the treatment of cancer and autoimmune diseases, today announced the approval of Phase I clinical trial of its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, by the China...
Find MoreFDA Approves Janssen's STELARA for the Treatment of Adults With Moderately to Severely Active Crohn’s Disease Janssen Biotech Inc. received approval from the U.S. FDA for STELARA (ustekinumab), used for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older). The drug is for the ...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.